Literature DB >> 22608917

L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer.

Sílvia Busquets1, Roberto Serpe, Míriam Toledo, Angélica Betancourt, Enrica Marmonti, Marcel Orpí, Fabrizio Pin, Eva Capdevila, Clelia Madeddu, Francisco J López-Soriano, Giovanni Mantovani, Antonio Macciò, Josep M Argilés.   

Abstract

BACKGROUND & AIMS: Tumour growth is associated with weight loss resulting from both adipose and muscle wasting.
METHODS: Administration of L-carnitine (1 g/kg body weight) to rats bearing the AH-130 Yoshida ascites hepatoma, a highly cachectic rat tumour.
RESULTS: The treatment results in a significant improvement of food intake and in muscle weight (gastrocnemius, EDL and soleus). These beneficial effects are directly related to improved physical performance (total physical activity, mean movement velocity and total travelled distance). Administration of L-carnitine decreases proteasome activity and the expression of genes related with this activity, such as ubiquitin, C8 proteasome subunit and MuRF-1. Interestingly, L-carnitine treatment also decreases caspase-3 mRNA content therefore suggesting a modulation of apoptosis. Moreover, addition of 50 μM of L-carnitine to isolated EDL muscles results in a significant decrease in the proteolytic rate suggesting a direct effect.
CONCLUSIONS: It can be concluded that L-carnitine supplementation may be a good approach for a multi-targeted therapy for the treatment of cancer-related cachexia.
Copyright © 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608917     DOI: 10.1016/j.clnu.2012.03.005

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  15 in total

Review 1.  Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2013-03-19       Impact factor: 5.614

Review 2.  Cachexia and pancreatic cancer: are there treatment options?

Authors:  Tara C Mueller; Marc A Burmeister; Jeannine Bachmann; Marc E Martignoni
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

3.  Supplemental carnitine affects the microRNA expression profile in skeletal muscle of obese Zucker rats.

Authors:  Janine Keller; Robert Ringseis; Klaus Eder
Journal:  BMC Genomics       Date:  2014-06-21       Impact factor: 3.969

4.  The early diagnosis and monitoring of squamous cell carcinoma via saliva metabolomics.

Authors:  Qihui Wang; Pan Gao; Xiaoyi Wang; Yixiang Duan
Journal:  Sci Rep       Date:  2014-10-30       Impact factor: 4.379

5.  Potential therapeutic role of L-carnitine in skeletal muscle oxidative stress and atrophy conditions.

Authors:  Anna Montesano; Pamela Senesi; Livio Luzi; Stefano Benedini; Ileana Terruzzi
Journal:  Oxid Med Cell Longev       Date:  2015-03-08       Impact factor: 6.543

6.  Efficacy of L-carnitine supplementation on frailty status and its biomarkers, nutritional status, and physical and cognitive function among prefrail older adults: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  M Badrasawi; Suzana Shahar; A M Zahara; R Nor Fadilah; Devinder Kaur Ajit Singh
Journal:  Clin Interv Aging       Date:  2016-11-17       Impact factor: 4.458

7.  Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise.

Authors:  Tatsuya Ito; Kiyoaki Tsukahara; Hiroki Sato; Akira Shimizu; Isaku Okamoto
Journal:  BMC Cancer       Date:  2021-06-28       Impact factor: 4.430

8.  Supplementation of carnitine leads to an activation of the IGF-1/PI3K/Akt signalling pathway and down regulates the E3 ligase MuRF1 in skeletal muscle of rats.

Authors:  Janine Keller; Aline Couturier; Melanie Haferkamp; Erika Most; Klaus Eder
Journal:  Nutr Metab (Lond)       Date:  2013-03-15       Impact factor: 4.169

9.  Phenotypic and metabolic features of mouse diaphragm and gastrocnemius muscles in chronic lung carcinogenesis: influence of underlying emphysema.

Authors:  Anna Salazar-Degracia; David Blanco; Mònica Vilà-Ubach; Gabriel de Biurrun; Carlos Ortiz de Solórzano; Luis M Montuenga; Esther Barreiro
Journal:  J Transl Med       Date:  2016-08-23       Impact factor: 5.531

10.  A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.

Authors:  Míriam Toledo; Fabio Penna; Francesc Oliva; Melania Luque; Angelica Betancourt; Enrica Marmonti; Francisco J López-Soriano; Josep M Argilés; Sílvia Busquets
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-05-14       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.